Ning Liao

819 total citations
16 papers, 256 citations indexed

About

Ning Liao is a scholar working on Cancer Research, Oncology and Molecular Biology. According to data from OpenAlex, Ning Liao has authored 16 papers receiving a total of 256 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Cancer Research, 8 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in Ning Liao's work include Breast Cancer Treatment Studies (7 papers), Advanced Breast Cancer Therapies (4 papers) and HER2/EGFR in Cancer Research (3 papers). Ning Liao is often cited by papers focused on Breast Cancer Treatment Studies (7 papers), Advanced Breast Cancer Therapies (4 papers) and HER2/EGFR in Cancer Research (3 papers). Ning Liao collaborates with scholars based in China, United States and Germany. Ning Liao's co-authors include Guochun Zhang, Yulei Wang, Lingzhu Wen, Chongyang Ren, Bo Chen, Li Cao, Liping Guo, Xuerui Li, Xi Chen and Hailin Tang and has published in prestigious journals such as Annals of Oncology, Gene and The Oncologist.

In The Last Decade

Ning Liao

16 papers receiving 253 citations

Peers

Ning Liao

ONCOL

PRM

PFM

Héctor Aquiles Maldonado-Martínez Mexico

Laura Arthur United Kingdom

Shaheenah Dawood United Arab Emirates

K.C. Aalders Netherlands

Shigeki Tanishima Japan

Ji‐Hye Oh South Korea

Isabel Heidrich Germany

Junjie Li China

Wenbo Zheng China

Christine Vietz United States

Héctor Aquiles Maldonado-Martínez Mexico

Ning Liao

132 ×1.0

106 ×0.9

ONCOL

119 ×1.1

82 ×1.4

PRM

35 ×0.7

PFM

Citations per year, relative to Ning Liao Ning Liao (= 1×) peers Héctor Aquiles Maldonado-Martínez

Countries citing papers authored by Ning Liao

Since Specialization

Citations

This map shows the geographic impact of Ning Liao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ning Liao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ning Liao more than expected).

Fields of papers citing papers by Ning Liao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ning Liao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ning Liao. The network helps show where Ning Liao may publish in the future.

Co-authorship network of co-authors of Ning Liao

This figure shows the co-authorship network connecting the top 25 collaborators of Ning Liao. A scholar is included among the top collaborators of Ning Liao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ning Liao. Ning Liao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Shao, Zhimin, Q. Zhang, Ning Liao, et al.. (2023). 107P Results in Chinese patients from pre-planned overall survival interim analysis in monarchE: Abemaciclib plus adjuvant endocrine therapy for high risk HR+, HER2- early breast cancer. ESMO Open. 8(1). 101331–101331. 1 indexed citations

Xu, Binghe, Huiping Li, Qingyuan Zhang, et al.. (2021). Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2– advanced breast cancer in Chinese women. Cancer Chemotherapy and Pharmacology. 88(1). 131–141. 11 indexed citations

Xiao, Weikai, Guochun Zhang, Bo Chen, et al.. (2021). Mutational Landscape of PI3K-AKT-mTOR Pathway in Breast Cancer: Implications for Targeted Therapeutics. Journal of Cancer. 12(14). 4408–4417. 28 indexed citations

Chen, Bo, Guochun Zhang, Guangnan Wei, et al.. (2020). Heterogeneity of genomic profile in patients with HER2-positive breast cancer. Endocrine Related Cancer. 27(3). 153–162. 26 indexed citations

Guo, Liping, Bo Chen, Guochun Zhang, et al.. (2020). The transcription factor CBFB mutations indicate an improved survival in HR+/HER2- breast cancer. Gene. 759. 144970–144970. 3 indexed citations

Zhu, Wenzhen, Chongyang Ren, Yulei Wang, et al.. (2020). <p>Prevalence of ESR1 Mutation in Chinese ER-Positive Breast Cancer</p>. OncoTargets and Therapy. Volume 13. 615–621. 6 indexed citations

Ren, Guosheng, Erwei Song, Da Pan, et al.. (2020). Current Status and Factors Influencing Surgical Options for Breast Cancer in China: A Nationwide Cross-Sectional Survey of 110 Hospitals. The Oncologist. 25(10). e1473–e1480. 38 indexed citations

Zhang, Guochun, et al.. (2019). GSTM1 polymorphism in Oncotype DX assay is a potential predictive factor for taxane-based neoadjuvant chemotherapy in estrogen receptor-positive Chinese breast cancer patients. Translational Cancer Research. 8(2). 655–663. 1 indexed citations

Zhang, Guochun, Bo Chen, Yulei Wang, et al.. (2019). Association between histone lysine methyltransferase KMT2C mutation and clinicopathological factors in breast cancer. Biomedicine & Pharmacotherapy. 116. 108997–108997. 29 indexed citations

10.

Chen, Bo, Hailin Tang, Xi Chen, et al.. (2018). Transcriptomic analyses identify key differentially expressed genes and clinical outcomes between triple-negative and non-triple-negative breast cancer. Cancer Management and Research. Volume 11. 179–190. 38 indexed citations

11.

Zhang, Guochun, Yulei Wang, Chongyang Ren, et al.. (2018). Presence of circulating tumor cells is associated with metabolic-related variables in postoperative patients with early-stage breast cancer. Chinese Journal of Cancer Research. 30(3). 340–350. 6 indexed citations

12.

Shi, Yunlong, et al.. (2017). Higher MCTS1 mRNA level in breast cancer may associate with an unfavorable outcome. Annals of Oncology. 28. v94–v94. 1 indexed citations

13.

Zhang, Guochun, Xueke Qian, Chongyang Ren, et al.. (2012). Pre-treatment hormonal receptor status and Ki67 index predict pathologic complete response to neoadjuvant trastuzumab/taxanes but not disease-free survival in HER2-positive breast cancer patients. Medical Oncology. 29(5). 3222–3231. 18 indexed citations

14.

Zhang, Guochun, Ning Liao, Xueke Qian, et al.. (2012). Accuracy and axilla sparing potentials of sentinel lymph node biopsy with methylene blue alone performed before versus after neoadjuvant chemotherapy in breast cancer: a single institution experience. Clinical & Translational Oncology. 15(1). 79–84. 7 indexed citations

15.

Zhang, Baoning, Xuchen Cao, Jiayi Chen, et al.. (2012). Guidelines on the diagnosis and treatment of breast cancer (2011 edition).. PubMed. 1(1). 39–61. 36 indexed citations

16.

Liu, Yan‐Hui, Fangping Xu, Ning Liao, et al.. (2010). Efficacy of intraoperative GeneSearch Breast Lymph Node (BLN) Assay for breast cancer metastasis detection in sentinel lymph node in Chinese patients. Cancer Science. 101(8). 1920–1924. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact